Navigation Links
Novel Actemra monotherapy in treating patients with early aggressive rheumatoid arthritis

The first Phase III study involving the use of Actemra in the treatment of rheumatoid arthritis has revealed that it is superior to conventional treatment modality that uses disease modifying anti-rheumatic drugs (DMARDs to inhibit // joint destruction. It has also been found to provide symptomatic relief and improve sensation of pain.

Rheumatoid arthritis is a debilitating autoimmune disease in which the lining of the joints becomes inflamed causing irreversible joint damage and destruction. Actemra (tocilizumab) is a humanized anti-human interleukin-6 (IL-6) receptor monoclonal antibody. A monoclonal antibody is used to denote antibodies derived from genetically identical group of cells, a clone. The novel mechanism of action of the antibody can eventually pave way for a new therapeutic option for the treatment of RA. Nearly 306 patients with early aggressive rheumatoid patients were taken up for the study and were randomized to receive either Actemra as monotherapy or traditional treatment. Actemra was administered at 8 mg/kg I.V for every three weeks while the other group underwent treatment for 52 weeks. The administration of anti-TNF agents and leflunomide were restricted in the control group.

At the end of the study, the results were compared which revealed that there was a substantial reduction in the progression of joint damage over a 1-year period. Actemra was superior to DMARDs in preventing both erosion and joint space narrowing. Furthermore, the results are more promising in patients with early, aggressive disease.

The tolerability of the monotherapy was comparatively much higher in the Actemra group. Although there was a slight increase in the cholesterol level initially, it soon stabilized around the upper limit of normal. There was no incidence of tuberculosis in the group studied.

Similar clinical trials are being conducted in Europe and US to determine the efficacy and safety of Actemra in combinati
'"/>




Page: 1 2

Related medicine news :

1. Novel "CYCLOSPORINE CAPSULE FORMULATION" to be launched
2. Novel biopsy technique for prostate cancer
3. Novel computer model for breast cancer
4. Novel research on liver cancer
5. Novel way to fight cancer
6. Novel test for bowel cancer
7. Novel Anti-Neutrophilic Effect produced by Salmeterol in mild asthma patients
8. Novel Therapy for Chronic Problem
9. Blood Sugar Kept In Control By Novel Protein
10. Novel antibiotic dressing developed for improved wound healing
11. United Kingdom Is Lagging In Novelty In The Field Of Pharmaceuticals
Post Your Comments:
(Date:7/9/2008)...sts.com, a leader in online insurance data and fre...rehensive information to help voters understand th...ealth reform as election 2008 nears. The site, whi...al on medical, auto, homeowners, and life insuranc... in coverage for themselves and their families. ,...
(Date:7/8/2008)...through adolescence may experience unhealthy level... always clear. In fact, many potential causes of ...on to be published in The Journal of Pediatrics ...alcohol and coffee consumption on weight gain in a...lleagues from Harvard Medical School, Brigham & Wo...
(Date:7/8/2008)...ly to develop disease , , TUESDAY, July...els of iron in men with peripheral arterial diseas...cording to a new study. , Lower levels of iron ...wer cancer incidence in observational studies. ,...d trial of men with peripheral arterial disease le...
(Date:7/8/2008)...Delays in Oxygen Orders, Lack of,Trained Technicia.../ -- The new Medicare,competitive bidding program ...and chaos for beneficiaries, physicians, hospital ...oviders across the country since it,was implemente...g program has triggered widespread disruptions in ...
Breaking Medicine News(10 mins):Health News:InsuranceSpecialists.com Looks at the Candidates and Health Reform 2Health News:InsuranceSpecialists.com Looks at the Candidates and Health Reform 3Health News:The Internet, alcohol and sleep 2Health News:Medicare Bidding Program Creates Major Problems for Physicians, Hospitals, and Beneficiaries Seeking Home Medical Equipment 2Health News:Medicare Bidding Program Creates Major Problems for Physicians, Hospitals, and Beneficiaries Seeking Home Medical Equipment 3Health News:Medicare Bidding Program Creates Major Problems for Physicians, Hospitals, and Beneficiaries Seeking Home Medical Equipment 4Health News:Medicare Bidding Program Creates Major Problems for Physicians, Hospitals, and Beneficiaries Seeking Home Medical Equipment 5
...aper on chronic obstructive pulmonary disease (COP...re often useful for patients of this disease to ha...c obstructive pulmonary disease (COPD) are lung di...d conditions like lung tissue destruction, airway ...
...e recent issue of the journal Thorax, researchers ...moking. Researchers have looked into the data prov...a firm connection between smoking and incidence of...subjects about 76% of them tested positive for tub...
...d a final guidance titled "Pharmacogenomic Data Su...roducts through the science of pharmacogenomics. P...entify sources of an individual's profile of drug ...le treatment option for this individual. This tech...
...nt component of mammal’s daily life and more so of...tation are known to sleep for over 18 hours. Howev...g in the sea. It has been reported in Nature that ...e wake most of the time in the first month. Their ...
Other Medicine News:Health News:Advent of New, More Effective and Personalized Medicines 2
(Date:7/7/2008)... Expanded HCV Development Presence Includes ANA598...tentially Complementary Mechanisms ..., July 7 /- Anadys Pharmace...t it is resuming clinical,investigation of the Tol...nt of chronic hepatitis C. Based on preclinical ph...
(Date:7/7/2008)... HONG KONG, July 7 /- OrbusNeich to...17th Annual Meeting of the Japanese Society of,Int... Bio-engineered R,stent has better outcomes when c...erico Piscione, M.D., the study,s principal,invest...sity of Naples,s,Division of Cardiology, Departmen...
(Date:7/6/2008)...Results are basis for CTI,s Marketing Authorizatio...er review by the EMEA, SEATTLE, July 7 /PRNewswir...daq: CTIC ; MTA) today announced the publication ...paring OPAXIO(TM) (paclitaxel poliglumex,CT-2103)... of PS 2,(performance status 2) patients with prev...
(Date:7/2/2008)... - Top-line Data Expected in Aug...-- Isolagen(TM), Inc. (Amex:,ILE) announced today ...its,Phase III clinical studies (IT-R-005/006) inve...nt of nasolabial folds, or wrinkles. The last,pers...y follow-up visit,and collation of this data has ...
Breaking Medicine Technology:Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV 2Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV 3Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV 4Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV 5Data Presented at Annual Meeting of Japanese Society of Interventional Cardiology Demonstrate OrbusNeich's Genous(TM) Bio-engineered R Stent(TM) Has Better Outcomes When Compared to Drug-Eluting Stents 2Data Presented at Annual Meeting of Japanese Society of Interventional Cardiology Demonstrate OrbusNeich's Genous(TM) Bio-engineered R Stent(TM) Has Better Outcomes When Compared to Drug-Eluting Stents 3Complete Study Results Comparing CTI's OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology 2Complete Study Results Comparing CTI's OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology 3Complete Study Results Comparing CTI's OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology 4Complete Study Results Comparing CTI's OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology 5Isolagen Completes Pivotal Efficacy Portion of Phase III Studies of Isolagen Therapy(TM) for Wrinkles 2Isolagen Completes Pivotal Efficacy Portion of Phase III Studies of Isolagen Therapy(TM) for Wrinkles 3Researchers discover molecular basis of a form of muscular dystrophy 3111 1Researchers discover molecular basis of a form of muscular dystrophy 3111 2LMS CALM 28R 29 receives high customer satisfaction scores in the 2008 KLAS Labor and Delivery report 17995 1LMS CALM 28R 29 receives high customer satisfaction scores in the 2008 KLAS Labor and Delivery report 17995 2LMS CALM 28R 29 receives high customer satisfaction scores in the 2008 KLAS Labor and Delivery report 17995 3BioForm Medical Acquires Facial Aesthetic Nerve Ablation Technology 17991 1BioForm Medical Acquires Facial Aesthetic Nerve Ablation Technology 17991 2BioForm Medical Acquires Facial Aesthetic Nerve Ablation Technology 17991 3BioForm Medical Acquires Facial Aesthetic Nerve Ablation Technology 17991 4BioForm Medical Acquires Facial Aesthetic Nerve Ablation Technology 17991 5Botaneco signs feasibility agreement with Croda to develop specialty crop oil formulation 4969 1Botaneco signs feasibility agreement with Croda to develop specialty crop oil formulation 4969 2Botaneco signs feasibility agreement with Croda to develop specialty crop oil formulation 4969 3
...nsive Survey Provides New Benchmark on MRSA,in Hea...ewswire-USNewswire/ -- The,following was released ...ide study of the prevalence of Methicillin-resista...t multi-drug resistant organism, in U.S. h...dy findings significantly exceed previous estimate...
...(June 21, 2007) Nymox Pharmaceutical,Corporation (...s,from the Company’s recently completed stud...PH) will be presented at a series of,upcoming U.S....outh,Central American Urological Association Meeti...resentations will be given by,leading clinical res...
Other Medicine Technology:Nationwide MRSA Prevalence Study to Demonstrate Full Scope of,'Superbug' Threat Facing U.S. Healthcare Facilities and Patients 2Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S.,Urology Meetings 2Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S.,Urology Meetings 3
...t immunoassay system built around the many positiv...rtant addition of Logic Driven Incubation (LDI). L...optimal performance with the fastest possible incu...uch as the cardiac biomarkers and HCG to be run in...
For The Detection Of Serum C-Peptide Levels.,Clinical Uses Of C-Peptide Measurement:, Evaluating patients with fasting hypoglycemia , Assisting in the classification of diabetes mellitus , D
Measles IgG ELISA test system is designed for the qualitative detection of IgG antibodies to Measles (Rubeola) virus in human serum, and is for in vitro diagnostic use.
Inquire
Medicine Products: